231 related articles for article (PubMed ID: 10331797)
1. European biotechnology turns East.
Sansom C
Nat Biotechnol; 1999 May; 17(5):437-9. PubMed ID: 10331797
[No Abstract] [Full Text] [Related]
2. The changing norms of the life sciences.
Shorett P; Rabinow P; Billings PR
Nat Biotechnol; 2003 Feb; 21(2):123-5. PubMed ID: 12560827
[No Abstract] [Full Text] [Related]
3. Report: EuroBioFund first annual forum in Helsinki.
Biotechnol J; 2007 Apr; 2(4):406-7. PubMed ID: 17407205
[No Abstract] [Full Text] [Related]
4. Building a life sciences innovation ecosystem.
Harrison KD; Kadaba NS; Kelly RB; Crawford D
Sci Transl Med; 2012 Oct; 4(157):157fs37. PubMed ID: 23100622
[TBL] [Abstract][Full Text] [Related]
5. Laying solid foundations for Europe.
Mattaj IW; Tocchini-Valentini GP
Nature; 2007 May; 447(7143):377-8. PubMed ID: 17522655
[No Abstract] [Full Text] [Related]
6. Japanese council urges reform of funding system.
Triendl R
Nat Biotechnol; 2002 Dec; 20(12):1176-8. PubMed ID: 12454656
[No Abstract] [Full Text] [Related]
7. The scientific muscle of Brazil's health biotechnology.
Ferrer M; Thorsteinsdóttir H; Quach U; Singer PA; Daar AS
Nat Biotechnol; 2004 Dec; 22 Suppl():DC8-12. PubMed ID: 15583686
[No Abstract] [Full Text] [Related]
8. Corridor at the crossroads: Michigan.
Smaglik P
Nature; 2002 Nov; 420(6913):4-5. PubMed ID: 12447399
[No Abstract] [Full Text] [Related]
9. Pay increases for nonfounder executives at private life sciences companies rebound.
Rychlik B
Nat Biotechnol; 2013 Mar; 31(3):259-61. PubMed ID: 23471072
[No Abstract] [Full Text] [Related]
10. France seeks to tighten its control over life sciences.
Butler D
Nature; 1995 Mar; 374(6519):206. PubMed ID: 7885435
[No Abstract] [Full Text] [Related]
11. What Brexit means for biotech.
Nat Biotechnol; 2016 Aug; 34(8):785. PubMed ID: 27504756
[No Abstract] [Full Text] [Related]
12. Demise of the life science company begins.
Niiler E
Nat Biotechnol; 2000 Jan; 18(1):14. PubMed ID: 10625374
[No Abstract] [Full Text] [Related]
13. Executive pay goes up at private life sciences companies despite tumultuous economic climate.
Rychlik B; Brown E
Nat Biotechnol; 2010 Jan; 28(1):99-100. PubMed ID: 20062043
[No Abstract] [Full Text] [Related]
14. Best of both worlds.
Smaglik P
Nature; 2003 Dec; 426(6967):706-7. PubMed ID: 14668875
[No Abstract] [Full Text] [Related]
15. [The report of scientific and scientific-organizational activity of Physiology Section of the Department of Biological Sciences of the Russian Academy of Sciences in 2006].
Maksimova IA; Sheremeta NG; Rosina NIa
Usp Fiziol Nauk; 2007; 38(3):87-105. PubMed ID: 17977234
[No Abstract] [Full Text] [Related]
16. Italian biologists left out in the cold.
Abbott A
Nature; 2001 Feb; 409(6821):652. PubMed ID: 11217825
[No Abstract] [Full Text] [Related]
17. Expanding the innovation pool.
Nat Biotechnol; 2012 Oct; 30(10):897. PubMed ID: 23051787
[No Abstract] [Full Text] [Related]
18. First Bush budget set to favour life sciences.
Davis M
Nature; 2001 Feb; 409(6823):969. PubMed ID: 11234034
[No Abstract] [Full Text] [Related]
19. Legal and social aspects of biotechnology in Poland.
Twardowski T
Acta Biochim Pol; 2005; 52(3):III-V. PubMed ID: 16475253
[No Abstract] [Full Text] [Related]
20. Hungary: basic science needs European support.
Hunyady L
Nature; 2004 Mar; 428(6978):17. PubMed ID: 14999258
[No Abstract] [Full Text] [Related]
[Next] [New Search]
